Baltimore, Maryland, United States Related Funds
Funds with similar focus
| Fund Name | Location |
| Cabinet Office - GOV.UK | - |
| Clearmind Capital | China, Hong Kong, Hong Kong Island |
| ENERGIIQ | Den Haag, The Netherlands, Zuid-Holland |
| Golden Summit Capital | - |
| Guerrilla Ventures | Delhi, Delhi, India |
| Junchuang Fund | China, Guangdong, Shenzhen |
| Lanhua Tengge Touzi | - |
| Mantucket Capital Management Corporation | Colorado, Greenwood Village, United States |
| POC Clinical Research | Japan, Tokyo |
| Visteon | Belleville, Michigan, United States |
Notable deals
| Company | Industry | Round Size | Date | Investors | Location |
Clasp Therapeutics | $150M | 20 Mar 2024 | Cambridge, Massachusetts, United States | ||
NextPoint Therapeutics | $42M | 14 Feb 2024 | Cambridge, Massachusetts, United States | ||
OnCusp Therapeutics | $100M | 04 Jan 2024 | New York, New York, United States | ||
Lassen Therapeutics | $85M | 19 Dec 2023 | San Diego, California, United States | ||
Entos | $100M | 03 Oct 2023 | Los Angeles, California, United States | ||
Rejuveron Life Sciences | $75M | 13 Sep 2023 | Zurich, Switzerland | ||
Georgiamune | $75M | 09 Aug 2023 | Gaithersburg, Maryland, United States | ||
Volastra Therapeutics | $60M | 07 Mar 2023 | New York, New York, United States | ||
NextPoint Therapeutics | $80M | 10 Jan 2023 | Cambridge, Massachusetts, United States |
– DNA Script announced it has raised $165m in a Series C financing round.
– The round was led by Coatue Management and Catalio Capital Management, whose representatives have joined as Board observers.
– The new funds will be used to accelerate expansion and commercialization of the company’s revolutionary SYNTAX Platform and broaden the portfolio of products powered by EDS.
– The SYNTAX Platform provides in-house DNA printing – without using toxic organic chemicals or extended delivery wait times from third-party DNA service providers – for labs of all sizes.
– Entos, Inc. (“Entos” or “the Company”), the creator of a cutting-edge platform combining AI-driven technology and automated synthetic development to design small-molecule therapeutics, announced the closing of a $53 million Series A.
– The financing round was led by Coatue, a leading technology investment firm, and Catalio Capital Management, a leading biomedical technology investment firm, with participation from OrbiMed and Sequoia Capital as well as existing investors Nexus Ventures and Freeflow.
1. You post comments at your own choice and risk. You bear the whole responsibility,related to their substance, content and the fact of publication. We shall not bear anyliability in respect of such comments.
2. While commenting, you shall use only actual, truthful and confirmed data. In thesame time you shall not use vulgar, abusive or defamatory language as well as expresshatred or call to violence or cruelty.
3. We do not intend to delete any comments on the website unless within our “noticeand take down” procedure.
4. We can moderate comments at any time.
5. While commenting, you are under the rule of our website’s terms of use and privacypolicy.
6. We retain our right to delete any comment or any other content of the website at ourwill in case we know or suppose such content is illegal or breaches any lawful right.
Review
- No reviews are submitted yet.
Sign up and get access to full fund profile and advanced analysis.
Full teamIndustries heatmapStages heatmapGeorgaphy breakdownCoinvestorsPortfolio analysisPerformance indexesLatest highlights
Unlock all data Latest deals
| Company | Industry | Round Size | Date | Investors | Location |
Clasp Therapeutics | $150M | 20 Mar 2024 | Cambridge, Massachusetts, United States | ||
NextPoint Therapeutics | $42M | 14 Feb 2024 | Cambridge, Massachusetts, United States | ||
OnCusp Therapeutics | $100M | 04 Jan 2024 | New York, New York, United States | ||
Lassen Therapeutics | $85M | 19 Dec 2023 | San Diego, California, United States | ||
Entos | $100M | 03 Oct 2023 | Los Angeles, California, United States | ||
Rejuveron Life Sciences | $75M | 13 Sep 2023 | Zurich, Switzerland | ||
Georgiamune | $75M | 09 Aug 2023 | Gaithersburg, Maryland, United States | ||
Volastra Therapeutics | $60M | 07 Mar 2023 | New York, New York, United States | ||
NextPoint Therapeutics | $80M | 10 Jan 2023 | Cambridge, Massachusetts, United States |
